Olivier Jarry leverages 35 years of passion for improving health and living standards throughout Europe, the Americas and Asia by creating sustainable, profitable growth, organically and through transactions, in the Life Sciences, Consumer Health, Nutrition and Consulting industries. Clients rely on his talent and insight to successfully address unique business or societal challenges.

Prior to joining Atlas, Mr. Jarry was an executive at life sciences companies, including Novartis, Bayer, Bristol-Myers Squibb where he delivered top-line and bottom-line growth ($1.4+ billion). Mr. Jarry has extensive experience managing businesses globally and in Corporate Strategy and Business Development & Licensing (M&A), including running substantial alliances. He concluded acquisitions, divestitures and alliances in excess of $1.1 billion in transaction value, including the negotiation of several 9-digit commercial and supply agreements in the Americas, Europe, Russia, India, China and Japan.

Mr. Jarry has also built fast growing companies in neuroimmunology, oncology, cell & gene therapy and digital therapeutics. He has deep connections in the healthcare space and investor community, which has allowed him to design collaboration agreements and plan exits.

In the 1990’s, Mr. Jarry led the post-merger integration practice for Accenture in Europe. He led pre-acquisition and post-acquisition projects in the Americas and Europe in a variety of industries. As the CFO of Danone in North America, he led several acquisitions including a $1.1 billion acquisition of a bottled water business.

Mr. Jarry is FINRA registered as an investment banker in the US (Series 7, 63, 79). He holds a TRIUM executive MBA (NYU Stern, LSE London, HEC Paris), a MEng from the French DOD (Ingénieur de l’Armement) and a MSc from Ecole Centrale de Paris.